Početna › T-stanični limfom › Kalifornija
Kliničke studije za T-stanični limfom u državi Kalifornija
13 studija za T-stanični limfom traži sudionike na lokacijama u državi Kalifornija.
Gradovi u državi Kalifornija
Službeni tekst studije (engleski)
Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma
- Cedars-Sinai Medical Center, Los Angeles
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 2. lis 2026. · NCT04803201Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
- City of Hope National Medical Center, Duarte
- University of California, Irvine, Irvine
- University of California San Francisco, San Francisco
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 25. ruj 2026. · NCT06561048BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
- City of Hope National Medical Center, Duarte
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 18. ruj 2026. · NCT04752826Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy
- Providence Saint Joseph Medical Center/Disney Family Cancer Center, Burbank
- City of Hope Comprehensive Cancer Center, Duarte
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine
- i još 4
U tijeku regrutacijaFaza 3
Od 18 do 75 godina · Oba spola · Ažurirano 14. ruj 2026. · NCT06724237A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL
- City of Hope Comprehensive Cancer Cente, Duarte
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 9. ruj 2026. · NCT06854653Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)
- Rady Children's Hospital, San Diego
U tijeku regrutacijaFaza 2
Od 1 do 18 godina · Oba spola · Ažurirano 10. kol 2026. · NCT06390319Duvelisib Maintenance for the Treatment of Peripheral T-Cell Lymphomas
- City of Hope Medical Center, Duarte
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 5. kol 2026. · NCT07293403Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma
- City of Hope Medical Center, Duarte
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 31. srp 2026. · NCT03011814Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphomas
- City of Hope Medical Center, Duarte
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 5. lip 2026. · NCT07278856A Registry for People With T-cell Lymphoma
- City of Hope Cancer Center (Data collection only), Duarte
- UNIVERSITY OF CALIFORNIA SAN DIEGO (Data collection only), San Diego
- University of California San Francisco (Data collection only), San Francisco
- i još 1
U tijeku regrutacijaOpažajna studija
Sve dobne skupine · Oba spola · Ažurirano 20. svi 2026. · NCT05978141MB-105 in Patients With CD5 Positive T-cell Lymphoma
- University of San Diego (UCSD)-Moores Cancer Center, San Diego
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 3. lis 2025. · NCT06534060Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
- City of Hope Medical Foundation, Duarte
- University of Southern California, Los Angeles
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 22. ruj 2025. · NCT04234048Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
- Children's Hospital Los Angeles, Los Angeles
- Children's Hospital Orange County, Orange
- UCSF School of Medicine, San Francisco
U tijeku regrutacijaFaza 1
Od 1 do 21 godina · Oba spola · Ažurirano 6. pro 2024. · NCT05476770Iz ClinicalTrials.gov, podaci preuzeti 5. lis 2026.. Svaka studija ima svoje uvjete prihoda; tim studije odlučuje tko se može priključiti.